Sanofi CEO: AI Ushers in a Great Era of Drug Discovery and Transforms Corporate Operations

Feb 25, 2024 15:04 CST Updated 15:04

Sanofi

Pharmaceutical R&D Developer

In 2023, Sanofi announced the next step in the company-wide digital transformation."All in" Artificial Intelligence and Data Science, accelerating breakthrough achievements for patients.

Driving this transformation is the company's CEO, Paul Hudson, who stated: "Sanofi's goal is to become the first large-scale AI-driven pharmaceutical company."

Recently,Sanofi CEO Paul Hudson Pens Article in Fortune Magazine, shared his views on artificial intelligence and the healthcare industry, as well as how Sanofi is driving this technology.

Paul Hudson believes:Artificial intelligence promises a golden age of drug discovery that could fundamentally change medicine — but only if we can make it happen.

Below is the original content:

Against the backdrop of economic uncertainty, high interest rates, talent shortages, and rising capital costs, artificial intelligence (AI) has become a top consideration for many industries, governments, and academic institutions.

Despite the long list of challenges the healthcare industry must overcome, there is reason to believe that through artificial intelligence, we are on the cusp of a great era of discovery that could fundamentally transform the field of medicine.

In the field of drug research and development (R&D), artificial intelligence has already demonstrated its potential.

Artificial intelligence and data analysis are driving breakthroughs that enable us to predict patient responses, increase the likelihood of clinical trial success, and identify personalized treatment plans for patients.

With the help of artificial intelligence, we are breaking new barriers, unlocking previously undruggable targets, and providing new therapies for patients who currently have no treatment options.

At Sanofi, the use of artificial intelligence to empower drug discovery and development is having a significant impact.

Our key AI models for small molecule drug discovery have a prediction accuracy rate of over 80% and are continuously improved through active learning.

Ninety percent of our disease targets are certified through single-cell genomics, and 75% of our small molecule projects are achieved through AI and machine learning (ML) compound design.

We create virtual patients to drive computer clinical trials, and ultimately, genomics-based precision medicine will help us achieve patient stratification.

We are using advanced active learning methods to improve the training of artificial intelligence models, requiring less data for model training.

AI learning emphasizes the key structural elements guiding the design cycle, making it shorter and cheaper, and leading to a higher success rate of new molecules.

WeIncreasing the number of clinical trials by 50%, To date, the value of our pipeline has quadrupled between 2019 and 2023.

We maintain continuous contact with the innovation ecosystem and adopt a "borderless" drug discovery strategy. 25% of our projects require collaboration with partners, which has doubled research productivity (in terms of dollars spent per clinical candidate molecule) and doubled our first-in-human trial projects.

Moreover, our way of operation is undergoing profound changes. Decision-making has shifted from an annual retrospective reporting capability to a dynamic and forward-looking decision intelligence approach, linking strategic choices with operational decisions and seeking to enhance our feedback loops.

Clearly, we are at a crossroads of massive expansion in medical discovery, but there are challenges in fully leveraging artificial intelligence, which will significantly impact the pharmaceutical industry's ability to unlock its potential.

Artificial Intelligence Regulation

Regional differences in regulations will guide restrictions on where AI is applied, the standards it must meet, and what constitutes high-risk applications.

Concerns about data quality, security, privacy, and trustworthiness may all slow down the adoption of artificial intelligence. Alliances and organizations are continuously emerging to help companies self-regulate.

As many companies begin to implement artificial intelligence across the enterprise, a strong data foundation and governance are crucial for preventing vulnerabilities.

The Impact of Drug Price Restrictions

The unintended consequences of the new drug pricing policy may reduce investment in promising R&D candidate drugs.

For example, the Inflation Reduction Act includes what some people call a "pill penalty" because it sets pricing for small-molecule drugs at 9 years and for biologics at 13 years. This essentially eliminates the incentive to pursue new breakthroughs and new uses for old drugs. The result could be increased investment in biologics and decreased investment in small-molecule drugs.

Biologics and small molecules are equally valuable. Small molecules can be taken orally, which is more convenient for many patients and crucial for treating many diseases.

Ways for Biotech Startups to Secure Funding

The biotech startup environment is a rich source of innovation that can complement large pharmaceutical R&D efforts. The synergy between the two stimulates drug discovery.

However, startups struggle in a high-interest-rate environment because product sales revenue often takes years to materialize. As costs rise, higher interest rates can also weaken the M&A intentions of large pharmaceutical companies.

In 2021, 111 biotechnology companies went public in the United States. In 2023, only 20 biotechnology companies went public.

At the same time, the pressure on biotechnology companies to merge or shut down is also increasing. According toEYHalf of the biotechnology companies do not have the cash needed to sustain operations for more than 18 months. Creating an attractive environment for biotechnology is key to maintaining the momentum of the R&D innovation engine.

Building Trust Through New Models of Clinical Trial Design

Decentralized clinical trial strategies enable patients from different regions of the world to participate, thereby benefiting from patient trust.

Adding considerations for the design that represents the most likely benefiting patient populations (especially underserved patients) and gaining insights from these patients can enhance patient acceptance of new therapies.

Decisions and actions on each of the above need to be made with caution, weighing the options, to ensure that we maximize the impact of new innovations, insights, and tools.

By strengthening collaboration with different stakeholders to identify obstacles in these unknown areas and develop solutions, we can drive faster discoveries.

Reference link:

https://fortune.com/2024/02/19/sanofi-ceo-ai-promises-great-era-drug-discovery-fundamentally-change-medicine/

—The End—

Recommended Reading